Current and historical daily PE Ratio for Gilead Sciences Inc (
LTS:0QYQ
) from 2018 to Apr 18 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Gilead Sciences stock (LTS:0QYQ) PE ratio as of Apr 18 2024 is 14.88.
More Details
Gilead Sciences Inc (LTS:0QYQ) PE Ratio (TTM) Chart
Gilead Sciences Inc (LTS:0QYQ) PE Ratio (TTM) Historical Data
View and export this data going back to 2018. Start your Free Trial
Total 1236
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Gilead Sciences PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-18 | 14.9 | 2024-02-13 | 16.3 |
| 2024-04-17 | 14.9 | 2024-02-12 | 16.5 |
| 2024-04-16 | 15.0 | 2024-02-09 | 16.4 |
| 2024-04-15 | 15.2 | 2024-02-08 | 16.3 |
| 2024-04-12 | 15.1 | 2024-02-07 | 16.7 |
| 2024-04-11 | 15.2 | 2024-02-06 | 17.3 |
| 2024-04-10 | 15.2 | 2024-02-05 | 17.1 |
| 2024-04-09 | 15.4 | 2024-02-02 | 17.3 |
| 2024-04-08 | 15.4 | 2024-02-01 | 17.4 |
| 2024-04-05 | 15.4 | 2024-01-31 | 17.5 |
| 2024-04-04 | 15.8 | 2024-01-30 | 17.4 |
| 2024-04-03 | 16.0 | 2024-01-29 | 17.7 |
| 2024-04-02 | 16.1 | 2024-01-26 | 17.9 |
| 2024-03-28 | 16.3 | 2024-01-25 | 17.8 |
| 2024-03-27 | 16.2 | 2024-01-24 | 17.6 |
| 2024-03-26 | 16.1 | 2024-01-23 | 17.6 |
| 2024-03-25 | 16.2 | 2024-01-22 | 17.4 |
| 2024-03-22 | 16.3 | 2024-01-19 | 19.2 |
| 2024-03-21 | 16.4 | 2024-01-18 | 19.1 |
| 2024-03-20 | 16.3 | 2024-01-17 | 19.1 |
| 2024-03-19 | 16.3 | 2024-01-16 | 19.1 |
| 2024-03-18 | 16.3 | 2024-01-15 | 19.1 |
| 2024-03-15 | 16.4 | 2024-01-12 | 19.1 |
| 2024-03-14 | 16.6 | 2024-01-11 | 18.8 |
| 2024-03-13 | 16.8 | 2024-01-10 | 18.6 |
| 2024-03-12 | 16.7 | 2024-01-09 | 18.9 |
| 2024-03-11 | 16.7 | 2024-01-08 | 18.5 |
| 2024-03-08 | 16.5 | 2024-01-05 | 18.7 |
| 2024-03-07 | 16.2 | 2024-01-04 | 18.7 |
| 2024-03-06 | 16.2 | 2024-01-03 | 18.6 |
| 2024-03-05 | 16.1 | 2024-01-02 | 18.4 |
| 2024-03-04 | 16.1 | 2023-12-29 | 18.1 |
| 2024-03-01 | 16.1 | 2023-12-28 | 17.9 |
| 2024-02-29 | 16.1 | 2023-12-27 | 17.2 |
| 2024-02-28 | 16.2 | 2023-12-22 | 16.9 |
| 2024-02-27 | 16.2 | 2023-12-21 | 16.9 |
| 2024-02-26 | 16.3 | 2023-12-20 | 17.0 |
| 2024-02-23 | 16.4 | 2023-12-19 | 17.1 |
| 2024-02-22 | 16.0 | 2023-12-18 | 17.2 |
| 2024-02-21 | 16.2 | 2023-12-15 | 17.3 |
| 2024-02-20 | 16.1 | 2023-12-14 | 17.6 |
| 2024-02-19 | 16.0 | 2023-12-13 | 17.4 |
| 2024-02-16 | 16.0 | 2023-12-12 | 17.3 |
| 2024-02-15 | 16.3 | 2023-12-11 | 17.2 |
| 2024-02-14 | 16.3 | 2023-12-08 | 16.8 |
Gilead Sciences Inc (LTS:0QYQ) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Gilead Sciences Inc
NAICS : 325412
SIC : 2834
ISIN : US3755581036
Share Class Description:
LTS:0QYQ: Ordinary SharesCompare
Compare
Traded in other countries / regions
GILD.USA0QYQ.UKGIS.GermanyGILD.ArgentinaGILD34.Brazil1GILD.ItalyGILD.AustriaGILD.MexicoGILD.ChileGILD.Peru IPO Date
2018-01-15Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers